On29 June 2023 ,Aker BioMarine ASA ("Aker BioMarine " or the "Company") announced a change to its group financial reporting and legal entity structure, separating into business units (1) Feed Ingredients; (2)Human Health Ingredients; (3) Consumer Health Ingredients; and (4) Emerging Businesses. As of1 January 2024 , the financial and legal reorganization has been completed and the business units are now operational as separate business units. Based on external interest for the Feed Ingredients business, the Company has decided to initiate a process to explore strategic alternatives for that business unit. Aker BioMarine Feed Ingredients is the world's largest krill harvester and producer of krill meal. Krill meal is a premium marine ingredient used in aquaculture feed, pet food and for extraction of krill oil for human consumption. Feed Ingredients owns and operates three specialized harvesting vessels and a support vessel. Production takes place inAntarctica utilizing an efficient and sustainable harvesting technology. Feed Ingredients has experienced strong growth over the recent years and realized FY23 adjusted revenues of approximatelyUSD 156 million and an adjusted cash EBITDA of approximatelyUSD 49 million , with a current run rate cash EBITDA atUSD 57 million . See further details in the Q4 2023 presentation. To assistAker BioMarine in this process, the Company has engagedArctic Securities , Carnegie andRabobank as financial advisers. For further information, please contactChristopher Robin Vinter , VP IR & Corporate Finance Mobile: +47 911 60 820 Email: Christopher.vinter@akerbiomarine.com AboutAker BioMarine Aker BioMarine is a leading biotech innovator and Antarctic krill-harvesting company developing krill-derived products for consumer health and wellness as well as animal nutrition. The company has a strong position in its industry and is the world's leading supplier of krill, the natural, powerful and health promoting source of nutrients from the pristine waters ofAntarctica .Aker BioMarine is listed onOslo Stock Exchange (AKBM). More information is available at www.akerbiomarine.com. This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act and contains information deemed to constitute inside information pursuant to the European Market Abuse Regulation. This announcement was published byChristopher Robin Vinter , VP IR & Corporate Finance ofAker BioMarine ASA on14 February 2024 .
Click here for more information
© Oslo Bors ASA, source